{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:25:40Z","timestamp":1790403940076,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Shenyang Pharmaceutical University, China"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejpb.2018.06.022","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T19:06:38Z","timestamp":1529435198000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Increased bioavailability of efonidipine hydrochloride nanosuspensions by the wet-milling method"],"prefix":"10.1016","volume":"130","author":[{"given":"Song","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2089-1982","authenticated-orcid":false,"given":"Hongyu","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.06.022_b0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1527-3466.2002.tb00084.x","article-title":"Efonidipine hydrochloride: A dual blocker of L- and T-Type Ca2+ channels","volume":"20","author":"Tanaka","year":"2002","journal-title":"Cardiov. Drug Rev."},{"key":"10.1016\/j.ejpb.2018.06.022_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003495-200969010-00002","article-title":"Development of newer calcium channel antagonists: therapeutic potential of efonidipine hydrochloride in preventing electrical remodelling during atrial fibrillation","volume":"69","author":"Ohashi","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2018.06.022_b0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10641960802627363","article-title":"Effects of efonidipine hydrochloride on heart rate and circulatory changes due to stress","volume":"31","author":"Morimoto","year":"2009","journal-title":"Clin. Exp. Hypertens"},{"key":"10.1016\/j.ejpb.2018.06.022_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejpb.2016.08.008","article-title":"Solid dispersions of efonidipine hydrochloride ethanolate with improved physicochemical and pharmacokinetic properties prepared with microwave treatment","volume":"108","author":"Otsuka","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.06.022_b0025","unstructured":"CDER\/FDA, Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release dosage forms based on a biopharmaceutical classification system, Center for Drug Evaluation and Research, 2000."},{"key":"10.1016\/j.ejpb.2018.06.022_b0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11051-008-9357-4","article-title":"Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system","volume":"10","author":"Gao","year":"2008","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ejpb.2018.06.022_b0035","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1211\/0022357023691","article-title":"Nanosuspensions: a promising drug delivery strategy","volume":"56","author":"Patravale","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.06.022_b0040","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/ja02086a003","article-title":"The rate of solution of solid substances in their own solutions","volume":"19","author":"Noyes","year":"1897","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2018.06.022_b0045","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1039\/C5CE00696A","article-title":"Controlled formation of barium fluoride nanocrystals by electric-assisted phase separation and precipitation","volume":"17","author":"Song","year":"2015","journal-title":"Cryst. Eng. Comm."},{"key":"10.1016\/j.ejpb.2018.06.022_b0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejpb.2015.02.031","article-title":"Process parameter dependent growth phenomena of naproxen nanosuspension manufactured by wet media milling","volume":"92","author":"Bitterlich","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.06.022_b0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejpb.2015.05.028","article-title":"Enhanced physical stabilization of fenofibrate nanosuspensions via wet co-milling with a superdisintegrant and an adsorbing polymer","volume":"94","author":"Azad","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.06.022_b0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijpharm.2015.05.070","article-title":"Preparation and characterization of paclitaxel nanosuspension using novel emulsification method by combining high speed homogenizer and high pressure homogenization","volume":"490","author":"Li","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.06.022_b0065","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.nano.2010.07.003","article-title":"Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface, application to amphotericin B","volume":"7","author":"Swarnali","year":"2011","journal-title":"Nanomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2018.06.022_b0070","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cherd.2013.02.008","article-title":"A study of the physical stability of wet media-milled fenofibrate suspensions using dynamic equilibrium curves","volume":"91","author":"Knieke","year":"2013","journal-title":"Chem. Eng. Res. Des."},{"key":"10.1016\/j.ejpb.2018.06.022_b0075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijpharm.2007.08.036","article-title":"Preparation and characterization of intravenously injectable nimodipine nanosuspension","volume":"350","author":"Xiong","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.06.022_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future","volume":"47","author":"M\u00fcller","year":"2001","journal-title":"Adv. Drug Deliver Rev."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118303771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118303771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:32:11Z","timestamp":1760545931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118303771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":16,"alternative-id":["S0939641118303771"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.06.022","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased bioavailability of efonidipine hydrochloride nanosuspensions by the wet-milling method","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}